Physician Wealth Advisors’s Metagenomi Therapeutics MGX Stock Holding History

Physician Wealth Advisors’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-610	Closed	-$1.45K	–	2171
2025 Q3	$1.45K	Hold	610	–	–	﹤0.01%	1367
2025 Q2	$903	Hold	610	–	–	﹤0.01%	1498
2025 Q1	$830	Buy	+610	New	+$1.45K	﹤0.01%	1214

Other funds holding MGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Physician Wealth Advisors's MGX Position: Q4 2025 in Review

Physician Wealth Advisors sold out of Metagenomi Therapeutics (MGX) in Q4 2025, closing a stake of 610 shares — an estimated $1.45K sold.

Physician Wealth Advisors first reported a position in MGX in Q1 2025 and held it in 3 quarters. The position peaked at $1.45K in Q3 2025. 56 funds tracked by Wall St. Rank hold MGX as of Q4 2025.

Physician Wealth Advisors reported no remaining Metagenomi Therapeutics position as of Q4 2025 after selling out during the quarter.
Physician Wealth Advisors sold 610 Metagenomi Therapeutics shares in Q4 2025, an estimated $1.45K.
Physician Wealth Advisors first reported a position in Metagenomi Therapeutics in Q1 2025 and held it in 3 quarters.
Physician Wealth Advisors's Metagenomi Therapeutics position peaked at $1.45K in Q3 2025.
56 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q4 2025.

Based on Physician Wealth Advisors's 13F filing for Q4 2025, filed 29 Jan 2026.